How Clinicians Should Evaluate New Wound Care Technologies

© 2026 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Wounds or HMP Global, their employees, and affiliates.

Advances in wound care technology are moving faster than ever, offering clinicians new opportunities to improve healing outcomes. At the same time, that pace of innovation has created a new challenge. The issue is no longer whether new products are available but how to determine which ones truly add clinical value and which simply add noise. In today’s crowded landscape, clinicians need a practical, evidence-informed way to decide what is worth adopting into real-world practice.

Before judging any new technology, it’s worth reflecting on your own clinical background and scope of practice. The types of products you’ve used extensively, the years you’ve spent managing complex wounds across different care settings, and any experience you’ve had with clinical trials, product evaluations, or formulary decisions all shape how you interpret product claims. A clinician with long-standing experience using hydrogels or antimicrobial dressings will naturally assess “innovation” differently from someone newer to the field, and that perspective matters. A solid understanding of core wound care technologies is particularly important when it comes to infection management. Because infection prevention and control remain central to successful healing, clinicians should be knowledgeable when it comes to commonly used antimicrobial agents such as silver, PHMB, iodine, honey, and other bioactive compounds. Many new products promise enhanced antimicrobial performance, but without a clear understanding of existing standards, it’s easy to overestimate what is truly new or different.

At the same time, clinicians should remain open to emerging technologies. These innovations are often exciting, but they must be evaluated carefully. The key questions are practical ones. Does the technology solve a real clinical problem? Is there meaningful evidence that its new features improve outcomes? Can it realistically be used in your care setting given the cost, training requirements, and workflow demands?

Innovation only matters if it translates into better healing, fewer infections, or measurable reductions in the cost of care. That is why a close look at the supporting evidence is essential. When reviewing new products, clinicians should consider whether studies were well designed, whether the outcomes measured were clinically relevant, and whether the research was peer-reviewed or generated primarily by industry. It is also important to ask whether the patient populations studied resemble the patients you treat every day.

Many clinicians today are also involved more directly in evaluation, selection, or even development of wound care technologies. If you serve as a clinical investigator, consultant, advisor, or formulary decision-maker, your perspective is especially valuable. Experience with trial design, quality improvement initiatives, or product assessments often makes it easier to recognize study limitations and judge whether a technology is realistically deployable outside of controlled research settings.

Adoption patterns across care environments also deserve careful consideration. A product may show promise, but its usefulness depends on whether similar advanced dressings are already used in hospitals, outpatient wound centers, or private practice, and whether reimbursement pathways exist. Even highly effective technologies can fail if they introduce burdens that outweigh their benefits in everyday care. Clinical demand should ultimately guide innovation, and new technologies should directly address these challenges. Innovation for its own sake is not enough; it must meaningfully improve care pathways and patient outcomes.

Finally, clinicians play an important role in determining whether new wound care technologies will scale successfully. Ease of use across diverse care settings, reliable distribution and supply chains, and clear value within outcome-driven care models all influence long-term adoption. Products that integrate smoothly into existing workflows are far more likely to achieve meaningful impact than those that remain niche solutions. As wound care continues to evolve, balancing enthusiasm for innovation with disciplined evaluation is essential keeping in mind the adage “all that glitters is not gold.”